Literature DB >> 34983358

M2PP: a novel computational model for predicting drug-targeted pathogenic proteins.

Shiming Wang1, Jie Li2, Yadong Wang3.   

Abstract

BACKGROUND: Detecting pathogenic proteins is the origin way to understand the mechanism and resist the invasion of diseases, making pathogenic protein prediction develop into an urgent problem to be solved. Prediction for genome-wide proteins may be not necessarily conducive to rapidly cure diseases as developing new drugs specifically for the predicted pathogenic protein always need major expenditures on time and cost. In order to facilitate disease treatment, computational method to predict pathogenic proteins which are targeted by existing drugs should be exploited.
RESULTS: In this study, we proposed a novel computational model to predict drug-targeted pathogenic proteins, named as M2PP. Three types of features were presented on our constructed heterogeneous network (including target proteins, diseases and drugs), which were based on the neighborhood similarity information, drug-inferred information and path information. Then, a random forest regression model was trained to score unconfirmed target-disease pairs. Five-fold cross-validation experiment was implemented to evaluate model's prediction performance, where M2PP achieved advantageous results compared with other state-of-the-art methods. In addition, M2PP accurately predicted high ranked pathogenic proteins for common diseases with public biomedical literature as supporting evidence, indicating its excellent ability.
CONCLUSIONS: M2PP is an effective and accurate model to predict drug-targeted pathogenic proteins, which could provide convenience for the future biological researches.
© 2021. The Author(s).

Entities:  

Keywords:  Disease; Pathogenic proteins; Prediction; Target

Mesh:

Substances:

Year:  2022        PMID: 34983358      PMCID: PMC8728953          DOI: 10.1186/s12859-021-04522-9

Source DB:  PubMed          Journal:  BMC Bioinformatics        ISSN: 1471-2105            Impact factor:   3.169


  88 in total

1.  Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.

Authors:  Michael Kloth; Vanessa Ruesseler; Christoph Engel; Katharina Koenig; Martin Peifer; Erika Mariotti; Helen Kuenstlinger; Alexandra Florin; Ursula Rommerscheidt-Fuss; Ulrike Koitzsch; Claudia Wodtke; Frank Ueckeroth; Stefanie Holzapfel; Stefan Aretz; Peter Propping; Markus Loeffler; Sabine Merkelbach-Bruse; Margarete Odenthal; Nicolaus Friedrichs; Lukas Carl Heukamp; Thomas Zander; Reinhard Buettner
Journal:  Gut       Date:  2015-04-28       Impact factor: 23.059

2.  Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.

Authors:  Tsuyoshi Ozawa; Yojiro Hashiguchi; Takahiro Yagi; Yoshihisa Fukushima; Ryu Shimada; Tamuro Hayama; Takeshi Tsuchiya; Keijiro Nozawa; Hisae Iinuma; Soichiro Ishihara; Keiji Matsuda
Journal:  Int J Colorectal Dis       Date:  2019-09-02       Impact factor: 2.571

3.  Urinary bisphenol A and its interaction with ESR1 genetic polymorphism associated with non-small cell lung cancer: findings from a case-control study in Chinese population.

Authors:  Jiaoyuan Li; Zhi Ji; Xia Luo; Ying Li; Peihong Yuan; Jieyi Long; Na Shen; Qing Lu; Qiang Zeng; Rong Zhong; Ying Shen; Liming Cheng
Journal:  Chemosphere       Date:  2020-04-19       Impact factor: 7.086

4.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.

Authors:  Laura Bonapace; Marie-May Coissieux; Jeffrey Wyckoff; Kirsten D Mertz; Zsuzsanna Varga; Tobias Junt; Mohamed Bentires-Alj
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

5.  Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

Authors:  Fiona H Blackhall; Melania Pintilie; Michael Michael; Natasha Leighl; Ronald Feld; Ming-Sound Tsao; Frances A Shepherd
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

6.  From genomics to chemical genomics: new developments in KEGG.

Authors:  Minoru Kanehisa; Susumu Goto; Masahiro Hattori; Kiyoko F Aoki-Kinoshita; Masumi Itoh; Shuichi Kawashima; Toshiaki Katayama; Michihiro Araki; Mika Hirakawa
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

7.  Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription.

Authors:  Gengyi Zou; Xiaotong Zhang; Lun Wang; Xiyang Li; Tianyu Xie; Jin Zhao; Jie Yan; Longlong Wang; Haoyu Ye; Shunchang Jiao; Rong Xiang; Yi Shi
Journal:  Theranostics       Date:  2020-05-22       Impact factor: 11.556

8.  Cannabidiol Overcomes Oxaliplatin Resistance by Enhancing NOS3- and SOD2-Induced Autophagy in Human Colorectal Cancer Cells.

Authors:  Soyeon Jeong; Bu Gyeom Kim; Dae Yeong Kim; Bo Ram Kim; Jung Lim Kim; Seong Hye Park; Yoo Jin Na; Min Jee Jo; Hye Kyeong Yun; Yoon A Jeong; Hong Jun Kim; Sun Il Lee; Han Do Kim; Dae Hyun Kim; Sang Cheul Oh; Dae-Hee Lee
Journal:  Cancers (Basel)       Date:  2019-06-05       Impact factor: 6.639

9.  Associating genes and protein complexes with disease via network propagation.

Authors:  Oron Vanunu; Oded Magger; Eytan Ruppin; Tomer Shlomi; Roded Sharan
Journal:  PLoS Comput Biol       Date:  2010-01-15       Impact factor: 4.475

10.  Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.

Authors:  Heather Spencer Feigelson; Lauren R Teras; W Ryan Diver; Weining Tang; Alpa V Patel; Victoria L Stevens; Eugenia E Calle; Michael J Thun; Mark Bouzyk
Journal:  Breast Cancer Res       Date:  2008-07-08       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.